Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4081/monaldi.2020.1300 http://scihub22266oqcxt.onion/10.4081/monaldi.2020.1300 32425013!ä!32425013 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32425013&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Monaldi+Arch+Chest+Dis 2020 ; 90 (2): ä Nephropedia Template TP {{tp|p=32425013|t=2020. COVID-19 and coagulative axis: review of emerging aspects in a novel disease |pdf=|usr=}}{{32425013}} gab.com Text COVID-19 and coagulative axis: review of emerging aspects in a novel disease JO: Monaldi Arch Chest Dis http://www.kidney.de/pget.php?&tw=1&pmid=32425013 #FOAvip Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients. Particularly, conventional coagulation parameters appear to be significantly altered in patients with poor prognosis. A wide-ranging cross- talk between coagulative haemostasis and inflammation, as well as the activation of coagulation cascade during viral infections, are well established. Another important evidence which may explain coagulation disorders in COVID-19 is the increase of thrombus formation under conditions of hypoxia. Despite the exact pathophysiological mechanism of coronavirus-induced thromboembolism needs to be further investigated, this finding suggests that it is good practice to assess the risk of thrombosis in COVID-19 patients to improvethe clinical management in terms of anticoagulation therapy. Anticoagulants, mainly low-molecular-weight heparin (LMWH), should be tailored in patients meeting sepsis induced coagulopathy (SIC) criteria or with markedly elevated D-dimer. In this context, further studies are needed to optimise the decision making in therapeutic approach. Twit Text FOAVip COVID-19 and coagulative axis: review of emerging aspects in a novel disease ????Monaldi Arch Chest Dis http://www.kidney.de/pget.php?&tw=1&pmid=32425013 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32425013 #FOAvip English Wikipedia <ref>{{Cite pmid|32425013}}</ref> COVID-19 and coagulative axis: review of emerging aspects in a novel disease #MMPMID32425013 Boccia M; Aronne L; Celia B; Mazzeo G; Ceparano M; D'Agnano V; Parrella R; Valente T; Bianco A; Perrotta F Monaldi Arch Chest Dis 2020[May]; 90 (2): ä PMID32425013show ga Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients. Particularly, conventional coagulation parameters appear to be significantly altered in patients with poor prognosis. A wide-ranging cross- talk between coagulative haemostasis and inflammation, as well as the activation of coagulation cascade during viral infections, are well established. Another important evidence which may explain coagulation disorders in COVID-19 is the increase of thrombus formation under conditions of hypoxia. Despite the exact pathophysiological mechanism of coronavirus-induced thromboembolism needs to be further investigated, this finding suggests that it is good practice to assess the risk of thrombosis in COVID-19 patients to improvethe clinical management in terms of anticoagulation therapy. Anticoagulants, mainly low-molecular-weight heparin (LMWH), should be tailored in patients meeting sepsis induced coagulopathy (SIC) criteria or with markedly elevated D-dimer. In this context, further studies are needed to optimise the decision making in therapeutic approach. |Betacoronavirus/isolation & purification[MESH] |Blood Coagulation Disorders/blood/epidemiology/*virology[MESH] |Blood Coagulation/physiology[MESH] |COVID-19[MESH] |Coronavirus Infections/*blood/epidemiology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*blood/epidemiology[MESH]COVID-19 and coagulative axis: review of emerging aspects in a novel d(epmc).pdf DeepDyve Pubget Overpricing